Zepzelca® (lurbinectedin) approved by the Ministry of Health in Oman for the treatment of metastatic Small Cell Lung Cancer
Stockholm, July 21, 2023 – Immedica’s product Zepzelca[®] (lurbinectedin) has received approval by the Ministry of Health in Oman for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Anders Edvell, CEO of Immedica commented: “SCLC is a type of lung cancer that tends to grow and spread fast. The medical need for these patients is huge and lurbinectedin has the potential to benefit the SCLC patients in Oman. We will work with our partner PharmaMar to support access of Zepzelca to these patients”.